Brain metastases in adult patients with melanoma of unknown primary in the Netherlands (2011–2020)

[1]  J. Grob,et al.  Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort. , 2022, Journal of the American Academy of Dermatology.

[2]  V. Ho,et al.  Prognostic factors among patients with brain metastases from cancer of unknown primary site , 2022, Journal of Neuro-Oncology.

[3]  H. Tawbi,et al.  Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: A real‐world study , 2021, Cancer medicine.

[4]  R. Dummer,et al.  Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. , 2021, European journal of cancer.

[5]  M. Aboian,et al.  Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis , 2021, Journal of Neuro-Oncology.

[6]  G. Hospers,et al.  Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy , 2021, Cancer Immunology, Immunotherapy.

[7]  J. Greenlee,et al.  Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy , 2021, Cancers.

[8]  A. Amini,et al.  Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling , 2020, Annals of Surgical Oncology.

[9]  D. Schadendorf,et al.  Melanoma brain metastases - Interdisciplinary management recommendations 2020. , 2020, Cancer treatment reviews.

[10]  M. Donia,et al.  The real‐world outcome of metastatic melanoma: Unknown primary vs. known cutaneous , 2019, International journal of cancer.

[11]  T. Gambichler,et al.  Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results , 2019, Oncoimmunology.

[12]  C. Verhoef,et al.  Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population‐based study , 2019, International journal of cancer.

[13]  M. Atkins,et al.  Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain , 2018, The New England journal of medicine.

[14]  J. Wilmott,et al.  Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. , 2018, The Lancet. Oncology.

[15]  V. Sondak,et al.  High frequency of brain metastases after adjuvant therapy for high‐risk melanoma , 2017, Cancer medicine.

[16]  Ying Zhang,et al.  Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[17]  R. Braun,et al.  Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching? , 2017, Melanoma research.

[18]  M. Gore,et al.  Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases , 2015, Pigment cell & melanoma research.

[19]  R. Dummer,et al.  Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. , 2014, European journal of cancer.

[20]  L. Kiemeney,et al.  Melanoma of unknown primary origin: a population-based study in the Netherlands. , 2013, European journal of cancer.

[21]  J. Wolchok,et al.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[22]  P. Hwu,et al.  Prognostic factors for survival in melanoma patients with brain metastases , 2011, Cancer.

[23]  D. Morton,et al.  Improved survival for stage IV melanoma from an unknown primary site. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Berg,et al.  MALIGNANT MELANOMA OF UNKNOWN PRIMARY ORIGIN. , 1963, Surgery, gynecology & obstetrics.

[25]  Yoon Young Choi,et al.  Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies. , 2015, Journal of the American Academy of Dermatology.

[26]  P. Allen.  ICDO — International Classification of Diseases for Oncology , 1991 .